title: Expansion and bioabsorption of the self-reinforced lactic and glycolic acid copolymer prostatic spiral stent.
abstract: OBJECTIVE
  Self-reinforced bioabsorbable stents can be made self-expanding due to the viscoelastic memory of the oriented bioabsorbable materials. A new self-expandable self-reinforced copolymer of lactic/glycolic acid, lactic/glycolic molar ratio 80:20 stent was developed to prevent postoperative urinary retention after procedures that induced prostatic edema. In in vitro experiments the expansion rate has been up to 100% during the first few hours at body temperature. We investigated the expansion rate and biodegradation of the self-reinforced lactic and glycolic acid copolymer prostatic spiral stent in vivo in the prostatic urethra.
  
  
  METHODS
  A total of 39 men, 52 to 84 years old, with lower urinary tract symptoms due to benign prostatic enlargement underwent interstitial laser coagulation of the prostate. A self-reinforced copolymer of lactic/glycolic acid, lactic/glycolic molar ratio 80/20 stent was inserted into the prostatic urethra at the end of the operation. The stent lumen diameter was 4.5 mm. The location and diameter of the lumen and degradation of the stent were studied with transrectal ultrasound at 1, 2, 4 and 6 months postoperatively. At 6 months patients underwent cystoscopy.
  
  
  RESULTS
  All except 1 patient voided on postoperative day 1. Mean lumen diameter was 7.4 mm. (range 6.2 to 8.2) at 1 month and 7.2 mm (range 6.2 to 7.5) at 2 months. At 4 months the stent was degraded into small pieces. No pieces of stent were found in the prostatic urethra on ultrasound or cystoscopy at 6 months. However, a portion of the spiral stent was found at the bottom of the bladder in 2 patients.
  
  
  CONCLUSIONS
  The speed and expansion rate of the self-reinforced copolymer of lactic/glycolic acid, lactic/glycolic molar ratio 80/20 stent was sufficient to lock the stent in place and ensure voiding in cases of edema induced bladder outlet obstruction. Strength retention greater than 2 months was long enough to avoid later impairments of voiding.
authors.affiliation: Department of Urology, University Hospital and Medical School, University of Tampere, Tampere, Finland.
authors.forename: S
authors.initials: S
authors.lastname: Laaksovirta
authors.forename: M
authors.initials: M
authors.lastname: Talja
authors.forename: T
authors.initials: T
authors.lastname: Välimaa
authors.forename: T
authors.initials: T
authors.lastname: Isotalo
authors.forename: P
authors.initials: P
authors.lastname: Törmälä
authors.forename: T L
authors.initials: TL
authors.lastname: Tammela
mesh_terms: D020341:Absorbable Implants; D000368:Aged; D000369:Aged, 80 and over; D004867:Equipment Design; D006801:Humans; D017075:Laser Coagulation / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D011098:Polyglactin 910; D011470:Prostatic Hyperplasia / Q000601:surgery*; D015607:Stents; D016055:Urinary Retention / Q000209:etiology / Q000517:prevention & control*
chemical_list: D011098:Polyglactin 910